By boosting innate immunity, researchers eradicate aggressive prostate cancer in mice

Thursday, March 9, 2017 - 15:52 in Health & Medicine

Cabozantinib, an FDA-approved drug for patients with certain types of thyroid or kidney cancer, was able to eradicate invasive prostate cancers in mice by causing tumor cells to secrete factors that entice neutrophils -- the first-responders of the immune system -- to infiltrate the tumor. This novel approach, utilizing the innate immune system, produced near-complete clearance of invasive prostate cancers within 48 to 72 hours.

Read the whole article on Science Daily

More from Science Daily

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net